346 related articles for article (PubMed ID: 11356943)
1. Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats.
Yoshisue K; Nagayama S; Shindo T; Kawaguchi Y
J Pharmacol Exp Ther; 2001 Jun; 297(3):1166-75. PubMed ID: 11356943
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
[TBL] [Abstract][Full Text] [Related]
3. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
4. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
[TBL] [Abstract][Full Text] [Related]
5. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y
Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578
[TBL] [Abstract][Full Text] [Related]
6. Diamine oxidase, a plasma biomarker in rats to GI tract toxicity of oral fluorouracil anti-cancer drugs.
Moriyama K; Kouchi Y; Morinaga H; Irimura K; Hayashi T; Ohuchida A; Goto T; Yoshizawa Y
Toxicology; 2006 Jan; 217(2-3):233-9. PubMed ID: 16278042
[TBL] [Abstract][Full Text] [Related]
7. [Effects of 18 alpha-glycyrrhizic acid on rat liver cytochrome P450 isoenzymes and phase II transferase].
Yang J; Peng RX; Kong R; Yu JP
Yao Xue Xue Bao; 2001 May; 36(5):321-4. PubMed ID: 12584850
[TBL] [Abstract][Full Text] [Related]
8. Dietary cholesterol-induced changes of xenobiotic metabolism in liver. II. Effects of phenobarbitone and carbon tetrachloride on activities of drug-metabolizing enzymes.
Hietanen E; Ahotupa M; Heikelä A; Laitinen M
Drug Nutr Interact; 1982; 1(4):313-27. PubMed ID: 6821390
[TBL] [Abstract][Full Text] [Related]
9. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Shirasaka T; Taguchi T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
[TBL] [Abstract][Full Text] [Related]
10. Role of small intestinal cytochromes p450 in the bioavailability of oral nifedipine.
Zhang QY; Kaminsky LS; Dunbar D; Zhang J; Ding X
Drug Metab Dispos; 2007 Sep; 35(9):1617-23. PubMed ID: 17567730
[TBL] [Abstract][Full Text] [Related]
11. Effect of vitamin A deficiency on hepatic and intestinal drug metabolizing enzymes in rats.
Gupta PH; Mehta S; Mehta SK
Biochem Int; 1989 Jul; 19(1):123-33. PubMed ID: 2505773
[TBL] [Abstract][Full Text] [Related]
12. Laboratory methods for ten hepatic toxification/detoxification parameters.
Kitchin KT
Methods Find Exp Clin Pharmacol; 1983 Sep; 5(7):439-48. PubMed ID: 6422171
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability.
Lampen A; Christians U; Guengerich FP; Watkins PB; Kolars JC; Bader A; Gonschior AK; Dralle H; Hackbarth I; Sewing KF
Drug Metab Dispos; 1995 Dec; 23(12):1315-24. PubMed ID: 8689938
[TBL] [Abstract][Full Text] [Related]
14. Pre- and postweaning development of drug-metabolizing enzyme activities in small intestine and liver of rats.
de Waziers I; Boisset M; Atteba S
Drug Metab Dispos; 1988; 16(2):310-5. PubMed ID: 2898352
[TBL] [Abstract][Full Text] [Related]
15. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.
Komatsu T; Yamazaki H; Shimada N; Nagayama S; Kawaguchi Y; Nakajima M; Yokoi T
Clin Cancer Res; 2001 Mar; 7(3):675-81. PubMed ID: 11297264
[TBL] [Abstract][Full Text] [Related]
16. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
17. The combined effects of garlic oil and fish oil on the hepatic antioxidant and drug-metabolizing enzymes of rats.
Chen HW; Tsai CW; Yang JJ; Liu CT; Kuo WW; Lii CK
Br J Nutr; 2003 Feb; 89(2):189-200. PubMed ID: 12575903
[TBL] [Abstract][Full Text] [Related]
18. Modulation of hepatic and renal drug metabolizing enzyme activities in rats by subchronic administration of farnesol.
Horn TL; Long L; Cwik MJ; Morrissey RL; Kapetanovic IM; McCormick DL
Chem Biol Interact; 2005 Apr; 152(2-3):79-99. PubMed ID: 15840382
[TBL] [Abstract][Full Text] [Related]
19. Concurrent subacute exposure to arsenic through drinking water and malathion via diet in male rats: effects on hepatic drug-metabolizing enzymes.
Naraharisetti SB; Aggarwal M; Sarkar SN; Malik JK
Arch Toxicol; 2008 Aug; 82(8):543-51. PubMed ID: 18528686
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
